Explore Porsolt’s Epilepsy White Paper Evaluating Future Antiepileptic Drugs – Screening Models and Mechanisms.
Epilepsy is a neurological disorder affecting millions worldwide, with approximately 30 to 40% of patients experiencing drug-resistant seizures. In this white paper, Porsolt explores screening models used to evaluate new antiepileptic drugs (AEDs). This document highlights the importance of in vitro, in vivo, and ex vivo models in identifying future drug candidates, particularly for addressing pharmacoresistant epilepsy.
Key takeaways from this white paper include:
- The evaluation of AED screening models, with a focus on innovative approaches for testing new treatments.
- The effects of antiepileptic drugs with different mechanisms of action, such as Carbamazepine, Levetiracetam, and Retigabine.
- Porsolt’s contribution to epilepsy research through preclinical models and reproducible results, providing a deeper understanding of the mechanisms underlying pharmacoresistance.
Porsolt offers its expertise in screening models and pharmacological mechanisms to researchers and pharmaceutical companies, helping to develop more effective treatments for patients with drug-resistant epilepsy.
Download the white paper now to discover how our evaluation models and expertise in mechanisms of action can enhance your therapeutic development projects for pharmacoresistant epilepsy.
